Human αIFN co-formulated with milk derived E2-CSFV protein induce early full protection in vaccinated pigs

Vaccine

Volumn 28, Issue 50, 2010, Pages 7907-7914

  Toledo, Jorge R ^a,b   Barrera, Maritza ^c   Farnós, Omar ^d   Gómez, Silvia ^a   Rodríguez, María P ^d   Aguero, Felix ^c   Ormazabal, Valeska ^a   Parra, Natalie C ^a   Suárez, Lester ^a   Sánchez, Oliberto ^a,b  

^a UNIVERSITY OF CONCEPCIÓN   (Chile)

^b Galactous Biotech Ltda   (Chile)

^c National Centre for Animal and Plant Health CENSA   (Cuba)

^d CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

Author keywords

E2 CSFV; Emergency vaccine; Human interferon; Subunit vaccine

Indexed keywords

GLYCOPROTEIN E2; HEBERON; RECOMBINANT ALPHA2B INTERFERON; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DRUG DESIGN; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENTIATION; GOAT; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; LYMPHOCYTIC INFILTRATION; MALE; MILK; NONHUMAN; NUCLEOTIDE SEQUENCE; PESTIVIRUS; PESTIVIRUS INFECTION; PRIORITY JOURNAL; RECTUM TEMPERATURE; SWINE;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CELL LINE; CLASSICAL SWINE FEVER; CLASSICAL SWINE FEVER VIRUS; GOATS; HUMANS; INTERFERON-ALPHA; MALE; MILK; RECOMBINANT PROTEINS; SWINE; VACCINES, SUBUNIT; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES;

EID: 78650230665     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.073     Document Type: Article

References (44)

1. Moennig V. Introduction to classical swine fever: virus, disease and control policy. Vet Microbiol 2000, 73:93-102.
2. Moennig V., Floegel-Niesmann G., Greiser-Wilke I. Clinical signs and epidemiology of classical swine fever: a review of new knowledge. Vet J 2003, 165:11-20.
3. Terpstra C., Tielen M.J. Antibody response against swine fever following vaccination with C-strain virus. Zentralbl Veterinarmed B 1976, 23:809-821.
4. de Smit A.J., Bouma A., van Gennip H.G., de Kluijver E.P., Moormann R.J. Chimeric (marker) C-strain viruses induce clinical protection against virulent classical swine fever virus (CSFV) and reduce transmission of CSFV between vaccinated pigs. Vaccine 2001, 19:1467-1476.
5. Floegel-Niesmann G. Marker vaccines and companion diagnostic tests for classical swine fever. Dev Biol 2003, 114:185-191.
6. Wehrle F., Renzullo S., Faust A., Beer M., Kaden V., Hofmann M.A. Chimeric pestiviruses: candidates for live-attenuated classical swine fever marker vaccines. J Gen Virol 2007, 88:2247-2258.
7. Toledo J.R., Sánchez O., Montesino R., Farnos O., Rodríguez M.P., Alfonso P., et al. Highly protective E2-CSFV vaccine candidate produced in the mammary gland of adenoviral transduced goats. J Biotechnol 2008, 133:370-376.
8. van Oirschot J.T. Vaccinology of classical swine fever: from lab to field. Vet Microbiol 2003, 96:367-384.
9. Ganges L., Núñez J.I., Sobrino F., Borrego B., Fernández-Borges N., Frías-Lepoureau M.T., et al. Recent advances in the development of recombinant vaccines against classical swine fever virus: cellular responses also play a role in protection. Vet J 2008, 177:169-177.
10. Becher P., Orlich M., Thiel H.J. RNA recombination between persisting pestivirus and a vaccine strain: generation of cytopathogenic virus and induction of lethal disease. J Virol 2001, 75(14):6256-6264.
11. Dong X.N., Chen Y.H. Marker vaccine strategies and candidate CSFV marker vaccines. Vaccine 2007, 25:205-230.
12. Holinka L.G., Fernandez-Sainz I., O'Donnell V., Prarat M.V., Gladue D.P., Lu Z., et al. Development of a live attenuated antigenic marker classical swine fever vaccine. Virology 2009, 384:106-113.
13. Hulst M.M., Westra D.F., Wensvoort G., Moormann R.J. Glycoprotein E1 of hog cholera virus expressed in insect cells protects swine from hog cholera. J Virol 1993, 67:5435-5442.
14. van Rijn P.A., van Gennip H.G., Moormann R.J. An experimental marker vaccine and accompanying serological diagnostic test both based on envelope glycoprotein E2 of classical swine fever virus (CSFV). Vaccine 1999, 17:433-440.
15. Sánchez O., Barrera M., Rodríguez M.P., Frías M.T., Figueroa N.E., Naranjo P., et al. Classical swine fever virus E2 glycoprotein antigen produced in adenovirally transduced PK-15 cells confers complete protection in pigs upon viral challenge. Vaccine 2008, 26:988-997.
16. Bouma A., De Smit A.J., De Jong M.C., De Kluijver E.P., Moormann R.J. Determination of the onset of the herd-immunity induced by the E2 sub-unit vaccine against classical swine fever virus. Vaccine 2000, 18:1374-1381.
17. Barrera M., Sánchez O., Farnós O., Rodríguez M.P., Domínguez P., Tait H., et al. Early onset and long lasting protection in pigs provided by a classical swine fever E2-vaccine candidate produced in the milk of goats. Vet Immunol Immunopathol 2010, 133:25-32.
18. Tarradas J., Argilaguet J.M., Rosell R., Nofrarías M., Crisci E., Córdoba L., et al. Interferon-gamma induction correlates with protection by DNA vaccine expressing E2 glycoprotein against classical swine fever virus infection in domestic pigs. Vet Microbiol 2010, 142:51-58.
19. Bracci L., Canini I., Venditti M., Spada M., Puzelli S., Donatelli I., et al. Type I IFN as a vaccine adjuvant for both systemic and mucosal vaccination against influenza virus. Vaccine 2006, 24:56-57.
20. Cheng G., Zhao X., Yan W., Wang W., Zuo X., Huang K., et al. Alpha interferon is a powerful adjuvant for a recombinant protein vaccine against foot-and-mouth disease virus in swine, and an effective stimulus of in vivo immune response. Vaccine 2007, 25:5199-5208.
21. Brockmeier S.L., Lager K.M., Grubman M.J., Brough D.E., Ettyreddy D., Sacco R.E., et al. Adenovirus-mediated expression of interferon-alpha delays viral replication and reduces disease signs in swine challenged with porcine reproductive and respiratory syndrome virus. Viral Immunol 2009, 22:173-180.
22. Bonjardim C.A. Interferons (IFNs) are key cytokines in both innate and adaptive antiviral immune responses-and viruses counteract IFN action. Microbes Infect 2005, 7:569-578.
23. Katze M.G., He Y., Gale M. Viruses and interferon: a fight for supremacy. Nat Rev Immunol 2002, 2:675-687.
24. Asano A., Kon Y., Agui T. The mRNA regulation of porcine double-stranded RNA-activated protein kinase gene. J Vet Med Sci 2004, 66:1523-1528.
25. Honda K., Takaoka A., Taniguchi T. Type I interferon gene induction by the interferon regulatory factor family of transcription factors. Immunity 2006, 25:349-360.
26. Wensvoort G., Terpstra C., Boonstra J., Bloemraad M., Van Zaane D. Production of monoclonal antibodies against swine fever virus and their use in laboratory diagnosis. Vet Microbiol 1986, 12:101-108.
27. Diaz de Arce H., Ganges L., Barrera M., Naranjo D., Sobrino F., Frías M.T., et al. Origin and evolution of viruses causing classical swine fever in Cuba. Virus Res 2005, 112:123-131.
28. -ΔΔCt Method. Methods 2001, 25:402-408.
29. Barrera M., Sánchez O., Prieto Y., Castell S., Naranjo P., Rodríguez M.P., et al. Thermal stress treatment does not affect the stability and protective capacity of goat milk derived E2-marker vaccine formulation against CSFV. Vet Immunol Immunopathol 2009, 127:325-331.
30. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proc R Soc Lond B: Biol Sci 1957, 147:258-267.
31. Le Bon A., Schiavoni G., D'Agostino G., Gresser I., Belardelli F., Tough D.F. Type I interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 2001, 14:461-470.
32. Braun D., Caramalho I., Demengeot J. IFN-alpha/beta enhances BCR-dependent B cell responses. Int Immunol 2002, 14:411-419.
33. Tough D.F., Borrow P., Sprent J. Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 1996, 272:1947-1950.
34. Hunter C.A., Gabriel K.E., Radzanowski T., Neyer L.E., Remington J.S. Type I interferons enhance production of IFN-gamma by NK cells. Immunol Lett 1997, 59:1-5.
35. Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999, 189:521-530.
36. Proietti E., Bracci L., Puzelli S., Di Pucchio T., Sestili P., De Vincenzi E., et al. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol 2002, 169:375-383.
37. de Avila Botton S., Brum M.C., Bautista E., Koster M., Weiblen R., Golde W.T., et al. Immunopotentiation of a foot-and-mouth disease virus subunit vaccine by interferon alpha. Vaccine 2006, 24:3446-3456.
38. Roitt I., Brostoff J., Male D. Immunology 2001, Mosby International Ltd., Madrid, Spain, p. 119-29. 6th ed.
39. Jordan L.T., Derbyshire J.B. Antiviral action of interferon-alpha against porcine transmissible gastroenteritis virus. Vet Microbiol 1995, 45:59-70.
40. Cummins J.M., Mock R.E., Shive B.W., Krakowka S., Richards A.B., Hutcheson D.P. Oral treatment of transmissible gastroenteritis with natural human interferon alpha: a field study. Vet Immunol Immunopathol 1995, 45:355-360.
41. Radwanski E., Perentesis G., Jacobs S., Oden E., Affrime M., Symchowicz S., et al. Pharmacokinetics of interferon alpha-2b in healthy volunteers. J Clin Pharmacol 1987, 27:432-435.
42. Rodríguez J.L., Valenzuela C., Marín N., Ferrero J., Ducongé J., Castillo R., et al. Comparative pharmacokinetics and pharmacodynamics of two recombinant human interferon alpha-2b formulations administered intramuscularly in healthy male volunteers. Biotecnol Apl 2000, 17:166-170.
43. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998, 161:1947-1953.
44. Moraes M.P., Chinsangaram J., Brum M.C., Grubman M.J. Immediate protection of swine from foot-and-mouth disease: a combination of adenoviruses expressing interferon alpha and a foot-and-mouth disease virus subunit vaccine. Vaccine 2003, 22:268-279.